For individuals battling Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the introduction of Tafamidis and Attruby represents a genuine advancement . These novel therapies stabilize the transthyretin protein, slowing its damaging build-up and alleviating the burden of th